Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Importance: The association between body composition (BC) and cancer outcomes is complex and incompletely understood. Previous research in non–small-cell lung cancer (NSCLC) has been limited to small, single-institution studies and yielded promising, albeit heterogeneous, results. Objectives: To evaluate the association of BC with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic NSCLC. Design, Setting, and Participants: This comprehensive multicohort analysis included clinical data from cohorts receiving treatment at the Dana-Farber Brigham Cancer Center (DFBCC) who received immunotherapy given alone or in combination with chemotherapy and prospectively collected data from the phase 1/2 Study 1108 and the chemotherapy arm of the phase 3 MYSTIC trial. Baseline and follow-up computed tomography (CT) scans were collected and analyzed using deep neural networks for automatic L3 slice selection and body compartment segmentation (skeletal muscle [SM], subcutaneous adipose tissue [SAT], and visceral adipose tissue). Outcomes were compared based on baseline BC measures or their change at the first follow-up scan. The data were analyzed between July 2022 and April 2023. Main Outcomes and Measures: Hazard ratios (HRs) for the association of BC measurements with overall survival (OS) and progression-free survival (PFS). Results: A total of 1791 patients (878 women [49%]) with NSCLC were analyzed, of whom 487 (27.2%) received chemoimmunotherapy at DFBCC (DFBCC-CIO), 825 (46.1%) received ICI monotherapy at DFBCC (DFBCC-IO), 222 (12.4%) were treated with durvalumab monotherapy on Study 1108, and 257 (14.3%) were treated with chemotherapy on MYSTIC; median (IQR) ages were 65 (58-74), 66 (57-71), 65 (26-87), and 63 (30-84) years, respectively. A loss in SM mass, as indicated by a change in the L3 SM area, was associated with worse oncologic outcome across patient groups (HR, 0.59 [95% CI, 0.43-0.81] and 0.61 [95% CI, 0.47-0.79] for OS and PFS, respectively, in DFBCC-CIO; HR, 0.74 [95% CI, 0.60-0.91] for OS in DFBCC-IO; HR, 0.46 [95% CI, 0.33-0.64] and 0.47 [95% CI, 0.34-0.64] for OS and PFS, respectively, in Study 1108; HR, 0.76 [95% CI, 0.61-0.96] for PFS in the MYSTIC trial). This association was most prominent among male patients, with a nonsignificant association among female patients in the MYSTIC trial and DFBCC-CIO cohorts on Kaplan-Meier analysis. An increase of more than 5% in SAT density, as quantified by the average CT attenuation in Hounsfield units of the SAT compartment, was associated with poorer OS in 3 patient cohorts (HR, 0.61 [95% CI, 0.43-0.86] for DFBCC-CIO; HR, 0.62 [95% CI, 0.49-0.79] for DFBCC-IO; and HR, 0.56 [95% CI, 0.40-0.77] for Study 1108). The change in SAT density was also associated with PFS for DFBCC-CIO (HR, 0.73; 95% CI, 0.54-0.97). This was primarily observed in female patients on Kaplan-Meier analysis. Conclusions and Relevance: The results of this multicohort study suggest that loss in SM mass during systemic therapy for NSCLC is a marker of poor outcomes, especially in male patients. SAT density changes are also associated with prognosis, particularly in female patients. Automated CT-derived BC measurements should be considered in determining NSCLC prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CT-based studies in lung cancer have evaluated muscle quantity and muscle attenuation as distinct components of body composition, and both have been associated with clinical outcomes (9, 10, 13, 14).”
In the citing paper
“Previous studies in patients with lung cancer have linked CT-derived measures of skeletal muscle, adiposity, and body composition with survival and other clinical outcomes (9–14).”
In the citing paper
“Body mass index (BMI) is widely used as a simple marker of body habitus and has been associated with cancer outcomes (9, 10).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr
Janssen, I., Heymsfield, S. B., Wang, Z., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.1.81 · Cited by 3,087
Sex differences in human adipose tissues – the biology of pear shape
Karastergiou, K., Smith, S. R., Greenberg, A. S., & Fried, S. K. (2012) · Biology of Sex Differences · doi:10.1186/2042-6410-3-13 · Cited by 1,109
Gender differences in strength and muscle fiber characteristics
Miller, A. E. J., MacDougall, J. D., Tarnopolsky, M. A., & Sale, D. G. (1993) · European Journal of Applied Physiology and Occupational Physiology · doi:10.1007/bf00235103 · Cited by 1,094
Appendicular skeletal muscle mass: effects of age, gender, and ethnicity
Gallagher, D., Visser, M., De Meersman, R. E., Sepúlveda, D., Baumgartner, R. N., Pierson, R. N., Harris, T., & Heymsfield, S. B. (1997) · Journal of Applied Physiology · doi:10.1152/jappl.1997.83.1.229 · Cited by 966
Jackson, A., Stanforth, P., Gagnon, J., Rankinen, T., Leon, A., Rao, D., Skinner, J., Bouchard, C., & Wilmore, J. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802006 · Cited by 694
Research works printed but not linked: 41
- Maurits, 2022, Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer—a multicenter population-based cohort study., Clin Nutr, 41, 131, 10.1016/j.clnu.2021.11.012 · DOI
- Pickhardt, 2021, Automated CT-based body composition analysis: a golden opportunity., Korean J Radiol, 22, 1934, 10.3348/kjr.2021.0775 · DOI
- Pickhardt, 2022, Value-added opportunistic CT screening: state of the Art., Radiology, 303, 241, 10.1148/radiol.211561 · DOI · Paper page
- Pickhardt, 2020, Automated CT biomarkers for opportunistic prediction of future cardiovascular events and mortality in an asymptomatic screening population: a retrospective cohort study., Lancet Digit Health, 2, e192, 10.1016/S2589-7500(20)30025-X · DOI · Paper page
- Rutkowski, 2020, Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study., J Immunother Cancer, 8, 8, 10.1136/jitc-2020-001117 · DOI
- Caan, 2018, Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer., JAMA Oncol, 4, 798, 10.1001/jamaoncol.2018.0137 · DOI · Paper page
- Lee, 2018, Subcutaneous fat distribution is a prognostic biomarker for men with castration resistant prostate cancer., J Urol, 200, 114, 10.1016/j.juro.2018.01.069 · DOI
- Brown, 2018, The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: a population-based cohort study (C-SCANS)., J Cachexia Sarcopenia Muscle, 9, 664, 10.1002/jcsm.v9.4 · doi:10.1002/jcsm.v9.4
- De Amorim Bernstein, 2018, Body composition predictors of therapy response in patients with primary extremity soft tissue sarcomas., Acta Radiol, 59, 478, 10.1177/0284185117723370 · DOI
- Kazemi-Bajestani, 2016, Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes., Semin Cell Dev Biol, 54, 2, 10.1016/j.semcdb.2015.09.001 · DOI · Paper page
- Tisdale, 2002, Cachexia in cancer patients., Nat Rev Cancer, 2, 862, 10.1038/nrc927 · DOI · Paper page
- Murphy, 2010, Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients., Clin Nutr, 29, 482, 10.1016/j.clnu.2009.11.006 · DOI
- Sheng, 2017, Adipocytes sequester and metabolize the chemotherapeutic daunorubicin., Mol Cancer Res, 15, 1704, 10.1158/1541-7786.MCR-17-0338 · DOI
- Crudele, 2021, Visceral adiposity and cancer: role in pathogenesis and prognosis., Nutrients, 13, 13, 10.3390/nu13062101 · DOI
- Pestine, 2018, Representation of obese participants in obesity-related cancer randomized trials., Ann Oncol, 29, 1582, 10.1093/annonc/mdy138 · DOI
- De Baerdemaeker, 2004, Pharmacokinetics in obese patients., Contin Educ Anaesth Crit Care Pain, 4, 152, 10.1093/bjaceaccp/mkh042 · DOI · Paper page
- Meng, 2023, Comprehensive guidance for antibiotic dosing in obese adults: 2022 update., Pharmacotherapy, 43, 226, 10.1002/phar.v43.3 · doi:10.1002/phar.v43.3
- Griggs, 2021, Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline udpdate., J Clin Oncol, 39, 2037, 10.1200/JCO.21.00471 · DOI
- Kichenadasse, 2020, Association between body mass inhibitor therapy for advanced non–small cell lung cancer., JAMA Oncol, 6, 512, 10.1001/jamaoncol.2019.5241 · DOI · Paper page
- McQuade, 2023, Association of body mass index with the safety profile of nivolumab with or without ipilimumab., JAMA Oncol, 9, 102, 10.1001/jamaoncol.2022.5409 · DOI
- Rosenquist, 2014, Development and reproducibility of a computed tomography-based measurement for upper body subcutaneous neck fat., J Am Heart Assoc, 3, 10.1161/JAHA.114.000979 · DOI
- Al-Sawaf, 2023, Body composition and lung cancer-associated cachexia in TRACERx., Nat Med, 29, 846, 10.1038/s41591-023-02232-8 · DOI
- Degens, 2019, The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer., Lung Cancer, 133, 130, 10.1016/j.lungcan.2019.05.021 · DOI
- Hansen, 2021, Measurement of body composition: agreement between methods of measurement by bioimpedance and computed tomography in patients with non–small cell lung cancer., Clin Nutr ESPEN, 44, 429, 10.1016/j.clnesp.2021.04.021 · DOI
- Guzik, 2017, The role of infiltrating immune cells in dysfunctional adipose tissue., Cardiovasc Res, 113, 1009, 10.1093/cvr/cvx108 · DOI · Paper page
- Yeoh, 2015, The association between subcutaneous fat density and the propensity to store fat viscerally., J Clin Endocrinol Metab, 100, E1056, 10.1210/jc.2014-4032 · DOI
- Baba, 2010, CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies., J Nucl Med, 51, 246, 10.2967/jnumed.109.068775 · DOI · Paper page
- Yamamoto, 2020, Imaging spectrum of abnormal subcutaneous and visceral fat distribution., Insights Imaging, 11, 24, 10.1186/s13244-019-0833-4 · DOI
- Mracek, 2011, Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients., Br J Cancer, 104, 441, 10.1038/sj.bjc.6606083 · DOI
- Rosenquist, 2015, Fat quality and incident cardiovascular disease, all-cause mortality, and cancer mortality., J Clin Endocrinol Metab, 100, 227, 10.1210/jc.2013-4296 · DOI · Paper page
- Kapoor, 2020, Adipose tissue density on CT as a prognostic factor in patients with cancer: a systematic review., Acta Oncol, 59, 1488, 10.1080/0284186X.2020.1800087 · DOI
- Murphy, 2014, Adipose tissue density, a novel biomarker predicting mortality risk in older adults., J Gerontol A Biol Sci Med Sci, 69, 109, 10.1093/gerona/glt070 · DOI
- Blaak, 2001, Gender differences in fat metabolism., Curr Opin Clin Nutr Metab Care, 4, 499, 10.1097/00075197-200111000-00006 · DOI · Paper page
- Wronska, 2012, Structural and biochemical characteristics of various white adipose tissue depots., Acta Physiol (Oxf), 205, 194, 10.1111/apha.2012.205.issue-2 · doi:10.1111/apha.2012.205.issue-2
- Wolfs, 2010, Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study., BMC Med Genomics, 3, 34, 10.1186/1755-8794-3-34 · DOI
- Bjørndal, 2011, Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents., J Obes, 2011, 10.1155/2011/490650 · DOI · Paper page
- Womersley, 1977, A comparison of the skinfold method with extent of ‘overweight’ and various weight-height relationships in the assessment of obesity., Br J Nutr, 38, 271, 10.1079/BJN19770088 · DOI · Paper page
- Gallagher, 1998, Muscle distribution: variations with body weight, gender, and age., Appl Radiat Isot, 49, 733, 10.1016/S0969-8043(97)00096-1 · DOI · Paper page
- Cortellini, 2020, Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events., Eur J Cancer, 128, 17, 10.1016/j.ejca.2019.12.031 · DOI · Paper page
- Duma, 2019, Sex differences in tolerability to anti–programmed cell death protein 1 therapy in patients with metastatic melanoma and non–small cell lung cancer: are we all equal?, Oncologist, 24, e1148, 10.1634/theoncologist.2019-0094 · DOI · Paper page
- Bridge, 2018, OR 2.0 Context-Aware Operating Theaters, Computer Assisted Robotic Endoscopy, Clinical Image-Based Procedures, and Skin Image Analysis 204–213
Cited by
Gouez, M., Pérol, O., Pialoux, V., Avrillon, V., Boussageon, M., Decroisette, C., Delrieu, L., El Hajj, H., Fournier, B., Gille, R., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010334 · Cited by 3
“While growing evidence highlights the importance of body composition for cancer outcomes and response to immunotherapy [37], our intervention did not lead to improvements in body composition.”
Sung, S., Choi, H. J., Jeong, S., Cho, W., Kim, Y. J., Cha, H., Min, C. H., & Kim, M. S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1946212
Metadata
- Authors
- Chaunzwa, T. L., Qian, J. M., Li, Q., Ricciuti, B., Nuernberg, L., Johnson, J. W., Weiss, J., Zhang, Z., MacKay, J., Kagiampakis, I., Bikiel, D., Di Federico, A., Alessi, J. V., Mak, R. H., Jacob, E., Awad, M. M., & Aerts, H. J. W. L.
- Affiliations
- Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Massachusetts
- Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
- AstraZeneca, Cambridge, England and Waltham, Massachusetts
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2024-06-01
- Volume
- 10
- Issue
- 6
- Pages
- 773
- ISSN
- 2374-2437
- Cited by
- 50
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. https://app.cochat.ai/papers/10.1001/jamaoncol.2024.1120
- The paper
- Chaunzwa, T. L., Qian, J. M., Li, Q., Ricciuti, B., Nuernberg, L., Johnson, J. W., Weiss, J., Zhang, Z., MacKay, J., Kagiampakis, I., Bikiel, D., Di Federico, A., Alessi, J. V., Mak, R. H., Jacob, E., Awad, M. M., & Aerts, H. J. W. L. (2024). Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2024.1120
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.